Table 1.
Patient demographics
| Tumor Compression | CIPN | Postsurgical | Postradiation | Total | |
|---|---|---|---|---|---|
| Total | n = 13 | n = 25 | n = 13 | n = 6 | N = 57 |
| Age, y, mean ± standard deviation | 50.92 ± 18.14 | 53.48 ± 11.22 | 46.23 ± 11.26 | 62.83 ± 7.22 | 52.23 ± 13.33 |
| Gender, n (%) | |||||
| Male | 9 (69.2) | 9 (36.0) | 2 (15.4) | 3 (50.0) | 23 (40.4) |
| Female | 4 (30.8) | 16 (64.0) | 11 (84.6) | 3 (50.0) | 34 (59.6) |
| Primary cancer, n (%) | |||||
| Germ cell tumors | 2 (15.4) | 1 (4.0) | – | – | 3 (5.3) |
| Gynecological | – | 2 (8.0) | – | – | 2 (3.5) |
| Skin | 2 (15.4) | 1 (4.0) | 2 (15.4) | – | 5 (8.8) |
| Breast | 1 (7.7) | 9 (36.0) | 3 (23.1) | – | 13 (22.8) |
| Colorectal | – | 1 (4.0) | – | – | 1 (1.8) |
| Lymphoma/leukemia | – | 5 (20.0) | – | 1 (16.7) | 6 (10.5) |
| Prostate | – | 1 (4.0) | – | – | 1 (1.8) |
| Lung | – | – | 2 (15.4) | – | 2 (3.5) |
| Esophageal | – | 1 (4.0) | 2 (15.4) | 4 (66.7) | 7 (12.3) |
| Multiple myeloma | – | 2 (8.0) | – | – | 2 (3.5) |
| Kidney | – | – | 1 (7.7) | – | 1 (1.8) |
| Pituitary | – | 1 (4.0) | – | – | 1 (1.8) |
| Pancreas | – | 1 (4.0) | – | – | 1 (1.8) |
| Nerve sheath | 5 (38.5) | – | 1 (7.7) | 1 (16.7) | 7 (12.3) |
| Bone/soft tissue | 2 (15.4) | – | 2 (15.4) | – | 4 (7.0) |
| Head and neck | 1 (7.7) | – | – | – | 1 (1.8) |
| Metastases, n (%) | |||||
| Yes | 4 (30.8) | 2 (8.0) | 1 (7.7) | 1 (16.7) | 8 (14.0) |
| No | 9 (69.2) | 23 (92.0) | 12 (92.3) | 5 (83.3) | 49 (86.0) |
| Location of tumor compression, n (%) | |||||
| Cranial nerve | 3 (23.1) | – | – | – | – |
| Nerve roots | 8 (61.5) | – | – | – | – |
| Plexus | 2 (15.4) | – | – | – | – |
| CIPN: causative regimen, n (%) | |||||
| Oxaliplatin | – | 1 (4.0) | – | – | – |
| Octreotide | – | 1 (4.0) | – | – | – |
| Docetaxel | – | 1 (4.0) | – | – | – |
| Exemestane | – | 1 (4.0) | – | – | – |
| Paclitaxel | – | 2 (8.0) | – | – | – |
| Cetuximab | – | 1 (4.0) | – | – | – |
| Paclitaxel/herceptin | – | 1 (4.0) | – | – | – |
| Paclitaxel/carboplatin | – | 2 (8.0) | – | – | – |
| Cisplatin/etoposide | – | 1 (4.0) | – | – | – |
| THP | – | 1 (4.0) | – | – | – |
| FOLFOX | – | 2 (8.0) | – | – | – |
| R-GEMOX | – | 1 (4.0) | – | – | – |
| ddAC | – | 2 (8.0) | – | – | – |
| RVd | – | 1 (4.0) | – | – | – |
| CyBorD | – | 1 (4.0) | – | – | – |
| AC-T | – | 2 (8.0) | – | – | – |
| FLAG-IDA | – | 1 (4.0) | – | – | – |
| Hyper-CVAD | – | 1 (4.0) | – | – | – |
| EPOCH | – | 1 (4.0) | – | – | – |
| HiDAC | – | 1 (4.0) | – | – | – |
| Type of chronic postsurgical pain after resection, n (%) | |||||
| Post-thoracotomy syndrome | – | – | 3 (23.1) | – | – |
| Postmastectomy syndrome | – | – | 3 (23.1) | – | – |
| Postsurgical pain after nephrectomy | – | – | 1 (7.7) | – | – |
| Other | – | – | 6 (46.2) | – | – |
| Location of radiation therapy, n (%) | |||||
| Head and neck | – | – | – | 4 (66.7) | – |
| Spine | – | – | – | 2 (33.3) | – |
THP=docetaxel, trastuzumab, pertuzumab; FOLFOX=folinic acid, fluorouracil, oxaliplatin; R-GEMOX=rituximab, gemcitabine, oxaliplatin; ddAC=dose dense doxorubicin, cyclophosphamide; RVd=lenalidomide, bortezomib, dexamethasone; CyBorD=cyclophosphamide, bortezomib, dexamethasone; AC-T=doxorubicin, cyclophosphamide, paclitaxel; FLAG-IDA=fludarabine, high-dose cytarabine, idarubicin, granulocyte-colony stimulating factor; hyper-CVAD=hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; EPOCH=etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; HiDAC=high-dose cytarabine.